Pharma

5 Key Drugs Critical to Johnson & Johnson's Future

If J&J's going to keep rewarding investors, it's going to need these top drugs to continue racking up sales.<p><b>Johnson & Johnson</b> (NYSE:JNJ) recently …

Stocks

NHS pays pharmaceutical companies millions for drugs developed with taxpayers’ money

The NHS is spending millions of pounds on medicines that were discovered with taxpayer-funded research, in what has been branded a “rip-off” by major …

Medicine

3 Things, October 21, 2017: Celgene's New Gamble, Pluristem Marches On ARS, Janssen Advances Their Rheumatology Program

Celgene's collaboration works ever onward in solid tumors.<p>Roche bows out of development in myelofibrosis.<p>Johnson & Johnson scores two new approvals …

Business

Lower drug prices? Trump has one idea, but insurance giant Anthem has another

The sky-high cost of prescription meds was back in the spotlight this week. First, President Trump said drug prices “are out of control” and drug companies are “getting away with murder.”<p>Then came news that the country’s second-largest health insurer, Anthem, will partner with CVS to launch its own …

Health Care

Amazon Is About To Disrupt The Drug Industry, But Not The Way Most Think

It’s now a foregone conclusion that Amazon.com will enter the healthcare sector. Every day there is another article on how Amazon is planning to dominate some new corner of the American economy. One day Amazon is taking down Grainger and Home Depot. The next it’s single-handedly taking down not …

Business

GlaxoSmithKline adult shingles vaccine wins U.S. approval

(Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline's (GSK.L) Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on …

U.S. Food and Drug Administration

Canada faces battle for pharmacare scheme to make medicines free

Canada’s universal healthcare system has one big shortcoming: it doesn’t cover the cost of prescription drugs, meaning many Canadians go without medication<p>In his campaign for universal publicly funded healthcare in the US, Bernie Sanders has repeatedly held up Canada’s system as an example, …

Canadian News

Shkreli Lawyer, on Trial Himself, Seeks Distance From Shkreli

Evan Greebel, a lawyer who once advised Martin Shkreli, went on trial this week on charges that he helped Shkreli defraud the company he founded, …

Business

The Business of Saving Lives

Foster City, Calif.<p>‘We don’t apologize for being highly profitable until our patents run out,” says the man seated in the barest office of any corporate leader I’ve visited. There’s almost nothing on the walls, and the occupant, John C. Martin, tells me it’s because he moved into the space only “at …

Opinion

Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.<p>Three of Merck's U.S. sales teams will be cut: primary care, disease-focused endocrinology and …

United States

Drug Development Costs Revisited

A recent paper on drug development costs did not impress me. But if possible, it impressed Matthew Herper at <i>Forbes</i> even less. That’s the one where …

Business

Big (and Hurting) Media on Drugs

Did the Washington Post overplay its opioid story because it spent so much money on it?<p>In 1997, The Wall Street Journal lent its editorial voice to those of cancer doctors and the Journal of the American Medical Association to warn that severe pain was badly under-treated by the U.S. medical …

Medical Journals

Merck plans to lay off 1,800 sales staffers in U.S. commercial shakeup

"These changes are part of ongoing companywide efforts to sharpen Merck’s focus on innovative R&D that addresses significant unmet medical needs and …

Johnson & Johnson

Celgene's Whiff Isn't the End of the World - Bloomberg Gadfly

You can't win them all.<p>Celgene Corp. announced Thursday evening that it would discontinue a late-stage trial of its pipeline drug mongersen in …

Stocks

Allergan: A Splitting Headache?

Another analyst is weighing in on the growing guesswork regarding the likelihood that <b>Allergan</b> (AGN) could be heading for a break up.<p>Early this week, …

Stocks

Biotech giant Celgene is abandoning a drug it bought for $710 million — and the stock is dropping

• <b>Celgene, a major biotech company, said on Thursday that it planned to stop developing a critical drug.</b>• <b><br>The drug, mongersen, was being tested to treat Crohn's disease, and may still be used to treat ulcerative colitis.</b>• <b><br>Celgene had paid $710 million to acquire the drug, which was anticipated to make $1</b> …

Business

Pharma firms bank on complex generics to push earnings growth

JM Financial said in a note that Cipla and Lupin have multiple inhalers in their pipelines, while injectables form a significant portion of the …

Scott Gottlieb

Biotechnology Industry- New Business For India

Biotechnology is the fast emerging sector in Indian Economy.<p>It is expected that this sector will play a major role in boosting Indian economy in …

India

Analysts shift focus from consumption, financial stocks to IT, pharma

Over the last month, the BSE IT Index gained 2.36% and the BSE Healthcare Index 2.86%, while the benchmark index Sensex lost 0.04%. Photo:</b> …

Business (India)

This year's hurricane season may cost insurers $95 billion

• <b>Three hurricanes that made landfall in the US and two in Mexico will cost insurers billions of dollars</b>• <b><br>One company says its payouts will reach about $3.6 billion</b><p>GENEVA (AP) — Hurricanes Harvey, Irma and Maria, as well as two recent earthquakes in Mexico likely cost the insurance industry about $95 …

Hurricane Season

WTO: Ending ban on IP cases is prescription for more disputes

US, Switzerland oppose two-year extension to moratorium; India, China, Brazil in favour<p>New Delhi, October 20:<p>The US and Switzerland have objected to …

Business (India)

The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs

Roche shares have continued to weaken as investors worry about the impact of generic erosion and the possibility that the company's platform oncology …

Business

Gilead Stock Climbs as FDA Approves Lymphoma Cancer Therapy Drug Yescarta

Gilead Sciences Inc. (GILD) stock gained 2% in early trading Thursday, Oct. 19, after the FDA approved the biopharmaceutical company's Yescarta …

Stocks

Most Eye Drops Are Too Big For The Human Eye, Wasting Money And Medicine

When you’re using eye drops and feel like you’re spilling half of each dose down your face, it’s not because you’re clumsy. You are, in fact, …

Consumer News

Roche Enters a Competitive Storm With Shaky Defenses

A punch in the face you see coming still hurts.<p>After years of dread, Roche Holding AG is finally seeing the impact of biosimilar 1 competition on one …

Cancer

How big pharma's money – and its politicians – feed the US opioid crisis

Tom Marino might have withdrawn from consideration as Trump’s drug czar, but drug money is coursing through the veins of Congress – contributing directly to an epidemic that kills thousands of Americans each year<p>Donald Trump was not wrong. Hours before his nominee for “drug czar” withdrew from …

News (U.S.)

RedHill Biopharma up 10% premarket following U.S. Orphan Drug tag for upamostat

• RedHill Biopharma (NASDAQ:RDHL) is up 10% premarket on light volume. Yesterday, the FDA designed MESUPRON (upamostat) an Orphan Drug for the …

Stock Markets

Reframing the Conversation on Drug Pricing

<i>Editor’s note:</i> <i>An earlier version of this paper was co-authored by Dr. Rosenblatt and Mr. Termeer before Mr. Termeer passed away in May 2017. In</i> …

Health Care

2 Great Stocks For Retirees

Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.<p>Just because you've retired …

Stocks

Abolish The FDA. It Does Patients More Harm Than Good

Lost in the country’s inevitable descent into single-payer health care is the role the federal government plays in the skyrocketing prices of both …

Conservative View